Radiotherapy is broadly used clinically to treat primary and metastatic malignancies in approximately 50% of all cancer patients. Although the accurate delivery of the irradiation dose has been greatly improved, many patients suffer from local tumor recurrences following radiotherapy. Therefore, efforts to improve the efficacy of radiotherapy via combination treatment with other treatment regimens could provide clinical benefit. Recently, high-dose ionizing radiation has been shown to induce cancer cell death and tumor-specific adaptive immune responses. Conversely, inadequate antitumor responses or radiation-induced suppressive immunity may also account for a large part of treatment failures. However, the mechanisms of how radiation modulates immunosuppressive factors and biological activities remain to be fully elucidated.

Immunosuppressive factors are utilized by the host to constrain immune responses and prevent immune hyperactivation from harming normal tissues. Cancers take advantage of this native ability by exploiting various immune escape mechanisms to persist despite anticancer treatments. Immune-checkpoint pathways have been shown to be major mechanisms of immune resistance. Checkpoint blockade immunotherapies, such as antibodies targeting programmed cell death ligand 1 (PD-L1) and its receptor (PDCD1, better known as PD-1), have significantly increased the objective response rate to ~20–30% in the treatment of several types of cancers. Although anti-PD-1 and anti-PD-L1 antibodies have provided a new benchmark for antitumor activity in immunotherapy, their scope of application could be broadened with the combination of other conventional treatments, especially radiotherapy. Therefore, it is imperative to investigate whether radiotherapy synergizes with PD-L1/PD-1 axis inhibitors in clinical settings.

We hypothesized the following potential principles providing rationale for the combination of radiation and anti-PD-L1/PD-1 axis inhibitors: 1) Irradiation increases tumor destruction and triggers immune infiltration into tumors, concomitantly with a radiation-induced local inflammatory responses stimulating an upregulation of PD-L1 expression to constrain local tissue damage, and 2) Irradiation-induced immunity and enhanced PD-L1 expression together provide a window of opportunity for robust pharmacological actions of PD-L1/PD-1 axis inhibitors, reducing radio-resistance and increasing the anti-PD-L1 immunotherapy response rate.

In order to test these theories, first, we determined the expression level of PD-L1 in different myeloid cell populations and tumor cells in response to radiation therapy. The upregulation of PD-L1 was observed in the irradiated tumors in mice, suggesting that alteration of PD-L1 levels in the tumor microenvironments may block the antitumor function of infiltrating effector T cells induced by irradiation. Next, we combined irradiation with anti-PD-L1 antibody therapy to treat 2 allograft tumor models, TUBO breast cancer and MC38 colon cancer. We found that radiation and anti-PD-L1 antibody synergized in both tumor models, whereas there was only a slight impact on tumor growth after radiation therapy alone. Furthermore, the combination treatment not only lead to prolonged antitumor...
The depletion experiments indicated that CD8+ T cells, but not CD4+ T cells, were required for the efficacy of the combined radiation and checkpoint blockade therapy. Combination therapy could also induce a robust tumor antigen-specific T cell response, confirming the pivotal contribution of CD8+ T cell effector functions. Thus, these results not only reveal that CD8+ T cells are essential for the synergy of irradiation and anti-PD-L1 antibody therapy, but also that the effector functions of replenished CTLs in the tumor microenvironment following irradiation are restored by PD-L1 blockade.

Accumulating evidence has shown that myeloid-derived suppressor cells (MDSCs) contribute to the attenuation of immune responses during cancer progression, including after treatment. This raises the possibility that the combinatorial therapeutic regimen used in our tumor models might also alter the distribution of MDSCs, unmasking the intensity of replenished CTLs functions. Our study revealed that concurrent therapy significantly and markedly reduced tumor-associated MDSCs in comparison to single therapy. It has been well documented that MDSCs regulate T-cell activation and proliferation by various routes, such as the induction of regulatory T cells, the release of oxidizing molecules, the amino acid deprivation of T cells, and interference of T-cell migration and viability. However, the increase of CTLs functions coincident with the decrease of MDSCs proportion prompted us to reconsider their potential interaction in this context. We hypothesized that CD8+ T cells induced by irradiation and anti-PD-L1 antibody are responsible for the elimination of tumor-infiltrating MDSCs. In our in vivo model, depletion of CD8+ T cells following combination therapies recovered the population of MDSCs within tumors. Immunofluorescence-based co-localization assay revealed that the residual Gr1+ cells and CD8+ T cells were located significantly closer spatially in tumors that received combination treatment, compared with untreated controls. An in vitro co-culture assay showed that activated CD8+ T cells induced an increase in MDSC apoptosis in a tumor necrosis factor (TNF)-dependent manner. Furthermore, blockade of TNF in vivo abrogated the efficacy of combination treatment. Collectively, these results indicate that combination of irradiation and anti-PD-L1 antibody therapies achieved effective tumor control by enhancing CTLs effector functions, which, in turn, negatively regulates the accumulation of MDSCs through TNF signaling.

This study is timely and clinically relevant as it not only reveals that PD-L1 blockade synergizes with radiation therapy, but also indicates that the combination reduces radio-resistance and increases host response to antibody treatment (Fig. 1). We also demonstrate that CD8+ T cells are essential in the treatment response, partly by inducing MDSC cell death (Fig. 1). This study broadens the scope of current endeavors to manipulate the suppressive tumor environment and provides new insights into the design of combination cancer therapies for clinical applications.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.
References

1. Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 2011; 11:239-53; PMID:21430696; http://dx.doi.org/10.1038/nrc3007

2. Liauw SL, Connell PP, Weichselbaum RR. New paradigms and future challenges in radiation oncology: an update of biological targets and technology. Sci Transl Med 2013; 5: 173sr2; PMID:23427246; http://dx.doi.org/10.1126/scitranslmed.3005148

3. Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, Beckett M, Sharma R, Chin R, Tu T, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009; 114:589-95; PMID:19349616; http://dx.doi.org/10.1182/blood-2009-02-206870

4. Liang H, Deng L, Chmura S, Burnette B, Liadis N, Darga T, Beckett MA, Lingen MW, Witt M, Weichselbaum RR, et al. Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing. J Immunol 2013; 190:5874-81; PMID:23630355; http://dx.doi.org/10.4049/jimmunol.1202612

5. Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med 2012; 366:2517-9; PMID:22658126; http://dx.doi.org/10.1056/NEJMe1205943

6. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239

7. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoai1200690

8. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS,et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-44; PMID:23724846; http://dx.doi.org/10.1056/NEJMoai1305133

9. Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, Fu YX. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 2014; 124:687-95; PMID:24382348; http://dx.doi.org/10.1172/JCI67313

10. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12:253-68; PMID:22437938; http://dx.doi.org/10.1038/nri3175